(Cancer of Unknown Primary) Is Opdivo Effective?

• December 13, 2021
• 1 min read

On November 26, 2021, Dr. Junko Tanizaki and colleagues from Kindai University Faculty of Medicine published results in Annals of Oncology from the NivoCUP Phase 2 clinical trial evaluating the efficacy and safety of the anti-PD-1 antibody Opdivo (nivolumab) in cancer of unknown primary (CUP) patients.

This multi-center, single-arm Phase 2 trial administered Opdivo (240 mg every 2 weeks, up to 52 cycles) to CUP patients (N=56), with objective response rate (ORR) as the primary endpoint. Of these patients, 45 had received one prior line of therapy.

The trial was initiated because CUP carries a poor prognosis, and immune checkpoint inhibitors have demonstrated efficacy across multiple cancer types. The study aimed to evaluate the therapeutic value of nivolumab in this difficult-to-treat population.

Results (in patients with prior treatment, N=45):

• Objective response rate (ORR): 22.2%
• Median progression-free survival (PFS): 4.0 months
• Median overall survival (OS): 15.9 months

Safety: The safety profile was consistent with existing nivolumab clinical trial data. No treatment-related deaths were reported.

Conclusion: Based on the NivoCUP trial results, Dr. Tanizaki and colleagues concluded that Opdivo demonstrated promising anti-tumor activity in CUP patients, potentially representing a new treatment option for this population.

Source: https://www.annalsofoncology.org/article/S0923-7534(21)04824-9/fulltext

• Immunotherapy

• Clinical Trial Medications

  • (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
  • (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
  • (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4